Summary of responses from each Australian institution identified as managing lung cancer patients, stratified by high (≥100) or low (≤99) annual case volume
| Annual cases n/N (%) | ||
| Low (≤99) | High (≥100) | |
| Total no institutions† | 23 | 55 |
| Public | 15/23 (65.2) | 49/55 (89.1) |
| Private | 8/23 (34.8)* | 6/55 (10.9) |
| Metropolitan | 12/23 (52.2) | 42/55 (76.4) |
| Regional | 11/23 (47.8) | 13/55 (23.6) |
| Has regular MDT | 19/23 (82.6) | 54/55 (98.2) |
| No regular MDT | 4/23 (17.4) | 1/55 (1.8) |
| Frequency of MDT | ||
| Weekly | 7/18 (38.9) | 42/53 (76.4) |
| Fortnightly | 11/18 (47.8)* | 11/53 (20.0) |
| EBUS on site | 8/23 (34.8) | 50/55 (90.9) |
| Medical oncology on site | 20/23 (87.0) | 53/55 (96.4) |
| Radiation oncology on site | 14/23 (60.9) | 42/55 (76.4) |
| Specialist lung cancer nurse on site | 6/22 (27.3)* | 33/53 (62.3) |
| If yes FTE (median) | 0.5 | 0.8 |
| Core MDT members per OCP guidelines | 8/21 (38.1) | 34/53 (64.2) |
| Full recommended MDT attendance per OCP guidelines | 0/21 | 0/53 |
| QA against National guidelines | ||
| None | 7/17 (41.2) | 9/53 (16.4) |
| Very infrequent | 3/17 (17.6) | 12/53 (22.6) |
| Yes, ad hoc | 4/17 (23.5) | 9/53 (17.0) |
| Yes, regularly | 3/17 (17.6) | 23/53 (43.3) |
All data presented as n (%).
*P<0.05, compared with high volume.
†The denominator for responses varied as not all questions were answered by every respondent.
EBUS, endobronchial ultrasound; FTE, (fraction of) full time equivalent; MDT, multidisciplinary team; OCP, Optimal Care Pathway; QA, quality assurance.